Sensei Biotherapeutics prices $200 million PIPE at $13.85 per share

Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics, Inc.

SNSE

0.00
  • Sensei Biotherapeutics entered a private investment in public equity financing to raise USD 200 million in gross proceeds through the sale of Series B Non-Voting Convertible Preferred Stock.
  • Investors received 14,440 shares of Series B Preferred Stock at USD 13,850 per share, equivalent to USD 13.85 per common share on an as-converted basis.
  • The financing closed on Feb. 20, 2026.
  • Each Series B preferred share is set to automatically convert into 1,000 common shares following stockholder approval, with the vote scheduled for June 10, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sensei Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-234882), on May 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.